7.75		2016¥°							
γ Λ	78	SSIFICATION					7		
						\		5725	895
Y.	77	ISSUE		/	VA .		THE POSITION		
	UTILITY. SERIAL NUMBER		PAT	A 1 0 1999)		TENT MBER		5725	895
	SERIAL NUMBER 08/528,858	FILING DAT 09/15/9		su	BCLASS	G	ROUP ART UI	EXAM	AINER
T STA	JED W. FAHE	Y, ELDÉRS)	BURG, MD:	PAUL T	1.1	BALTIMO	RE, MD.		Uma
APPLICANTS					5 · · · · · · · · · · · · · · · · · · ·				
*	**CONTINUIN VERIFIED	B DATA***	长水水水水水水水	i de perderak de de de de }	kok j				
	· IAW			Į.			*		
	FOREIGN/PO	! T APPLICA	ATTONG*	sides sides sides sides sides sides side	: 36:	•			
	VERIFIED	er mit i kandi saer	4 E 3 (2)(4(2) to an an	ar de de spe de de de de	· · · · · · · · · · · · · · · · · · ·				
	14w							in the second se	
	المستدر الي	. 1				A STATE OF THE STATE OF			13. 7.4
					*				
	FOREIGN FILI	 NG LICENS	E GRANTE	D 12/19/	95	淮水水 水	* SMALL	ENTITY!	本本本
Fo: 35	reign priority claimed USC 119 conditions met	□ yes □ no	AS FILED	STATE OR SHI	EETS TOTAL WGS. CLAIMS	INDEP. CLAIMS	FILING FEE RECEIVED	ATTOR	NEY'S ET NO.
For 35	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L	yes no no Examiner's initial	AS FILED	STATE OR SH	EETS TOTAL	INDEP. CLAIMS	FILING FEE RECEIVED	ATTOR	NEY'S
Fo: 35	reign priority claimed USC 119 conditions met rified and Acknowledged	yes one Examiner's initial ARDNER	AS FILED	STATE OR SHI	EETS TOTAL WGS. CLAIMS	INDEP. CLAIMS	FILING FEE RECEIVED	ATTOR	NEY'S ET NO.
For 35	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON	yes no no yes no no yes no no no yes no	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL WGS. CLAIMS	S INDEP. CLAIMS	FILING FEE RECEIVED \$2,084	ATTOR	NEY'S ET NO.
For 35	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500	yes no no yes no no yes no no no yes no	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL WGS. CLAIMS	NDEP. CLAIMS 7 13	#2,084	ATTOR DOCKE	NEY'S ET NO.
ADDRESS As	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON	yes no no yes no no yes no no no yes no	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL WGS. CLAIMS	NDEP. CLAIMS 7 13	#2,084	ATTOR	NEY'S ET NO.
ADDRESS As	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON METHOD OF F	Examiner's initial ARDNER ET NW DC 20007- REPARING	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL WGS. CLAIMS	NDEP. CLAIMS 7 13	#2,084	ATTOR DOCKE	NEY'S ET NO.
ADDRESS As	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON	Examiner's initial ARDNER ET NW DC 20007- REPARING	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL WGS. CLAIMS	S CLIFEROUS U.S. DEPT	FILING FEE RECEIVED \$2,084	ATTOR DOCKE	O-436L (Rev
ADDRESS As	reign priority claimed USC 119 conditions met rified and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON METHOD OF F	Examiner's initial ARDNER ET NW DC 20007- REPARING CATION LY WANCE MAILE	AS FILED	STATE OR SHI	EETS TOTAL WGS. CLAIMS	S CLIFEROUS U.S. DEPT	FILING FEE RECEIVED \$2,084 SEEDS OF COMM/I	ATTOR DOCKE	O-436L (Rev
ADDRESS As	PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO SUITE SOO MASHINGTON	Examiner's initial ARDNER ET NW DC 20007- REPARING CATION LY WANCE MAILE - 9.7 FEE	AS FILED	STATE OR SHI COUNTRY DR'	EETS TOTAL CLAIMS 2 4	S CLAIMS 7 13	\$2,084 \$2,084 \$CL/	ATTOR DOCKE ACCOUNT OF THE PART & TM—PT ADDICATIONS EXAMPLES ALLOW Print C DRAWING:	O-436L (Rec
ADDRESS As	reign priority claimed USC 119 conditions met rifled and Acknowledged FOLEY AND L 3000 K STRE SUITE 500 WASHINGTON METHOD OF F PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO	Examiner's initial ARDNER ET NW DC 20007- REPARING CATION LY WANCE MAILEI - 977	AS FILED S 109 A FOOD P Assistant E	STATE OR SHI	ROM CRUC	INDEP. CLAIMS 13 IFEROUS U.S. DEP1 To	FILING FEE RECEIVED \$2,084 \$2,084 SEEDS OF COMM./6 CL. tal Claims eets Drwg.	ATTOR DOCKE A 65	O-436L Revaluation
ADDRESS As	PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO SOUR STREE SUITE 500 WASHINGTON METHOD OF F PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO SOURCE Amount Due 645.00	Examiner's initial ARDNER ET NW DC 20007- REPARING CATION LY WANCE MAILE! FEE Date Paid	AS FILED 5109 A FOOD P Assistant E	XAMINET LESLIE WO GROUP 13 WMA 8/13	ROM CRUIC NG MINER 00	U.S. DEP1 To	\$2,084 \$2,084 \$CL/	ATTOR DOCKE ACCOUNT OF THE PART & TM—PT ADDICATIONS EXAMPLES ALLOW Print C DRAWING:	O-436L (Review)
ADDRESS As	PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO SUITE SOU WASHINGTON PARTS OF APPLIC FILED SEPARATE NOTICE OF ALLO SUITE SOU WASHINGTON	Examiner's initial ARDNER ET NW DC 20007- REPARING CATION LY WANCE MAILE! FEE Date Paid	AS FILED 5109 A FOOD P Assistant E	STATE OR SHE COUNTRY DR	ROM CRUC NG MINER OO APrimary E OR ISSUE disclosed herein	U.S. DEPT To To The state of	FILING FEE RECEIVED \$2,084 \$ SEEDS OF COMM./I	ATTOR DOCKE ACCOUNT OF THE POT THE PO	O-436L Rev.

ISSUE FEE IN TIME
1-B1

Exhibit 1-B(i)

POSITION		ID NO.		DATE
CLASSIFIER		~ 2	/ //	0/26/95
EXAMINER		249		1/14/93
TYPIST	*	334	5 //	5/19/95
VERIFIER		341		2/19/98
CORPS CORR.		100	- '	~// */
SPEC. HAND				
FILE MAINT.				
DRAFTING				

INDEX OF CLAIMS

	С	laim				Dat	e			
		1 75	8	12	12	8	ļ .	1	1:	Ī
:	Final	Original	8 2 1 9 V		教	Dat		1		1
		ō	196	M	<u> </u>	LK	1			Ľ.
: [Ø	X	N	N		L	L		
	أمييا	2	Ц	Ш				L		
		β.	Ш	Ш	\Box		L	L		Ŀ
		A	LI		Ш					
Ġ	ينا	5	Ш	Ш	Ш	L.,				
	4	6	ட	4	11	أتنا	-		_	<u> </u>
;		7	Ш	1	11	<u> </u>	<u> </u>	<u> </u>		
٠.	4.79	8		11.			<u> </u>		<u> </u>	
		9		4	1	<u> </u>		_	-	
	A A	10			H		<u> </u>			<u> </u>
	. १		4	1	H	<u> </u>	_	-		
	11.1	(2) (3)		-	H	إببنا		-		
	f	13		4	-+	\Box		<u> </u>	-	
		40-	\mathbb{H}	+	H	ابنا		1		إخنيا
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	GI TE	+	+	++	-				L.
	111	10	+	4	- -					L
1		ib	+	+	++	-				
4	5.7	14 15 16 17 18 19 20 21	+	+				_	\vdash	
ŀ		20	+	4	إلما		-	-	\vdash	
1	<u> </u>	5	+	7	Ñ				اخا	
1	<u>۲</u>	22	+	1	171	-		<u> </u>		\dashv
}	23	22	+1		4	+		إحنبا	إحضا	
	2	24	++	+	1	+		<u> </u>		
ŀ	귀	24 25 26 27 28	+	7	+	+		-		
ŀ		26	+	7	-	-	-		-	
1	4	20	+	Ň	V	\dashv	-			
+	7.	28	1 2	1		=		÷		
1	3	29	+	1	1	1				
ŀ	9	29 30	11	++		1		\dashv		
1	10	31	11	- 11	-	1				
- [W	32		\exists						
Ī	12	33 34	T		11					
1	ผน	34	П	V	-=	2				
	<u></u>	30	Д	V	\mathbf{M}	\Box				
	4]	34 36 36	\prod	V	2	2	\Box		\Box	
1	15 !	(3/)		V	-	3				
1	10[38 39 30 1 30 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		V	-					
. }	_	1		V	N	\dashv		_		
-	_	44	1#	4	++		_		\dashv	
+	4	47		4	+1				-	
F		**		4	+				_	
1	_	43		+	+	-+	\dashv	- 1		-
+		*		+	++		+			
+		Th		+	-	-+	-			
+		3	1	Ň	N	+		-+		-
-		48	+	14	14	+	-	\dashv	+	
F		49	- -			\dashv		-		\dashv
F		50	-		\dashv	-+				\dashv
ئاي	4	1								
1	Α.		£ £						1 1	,

	U	aim			wig.	. Da	te			
					-		T	Γ		
	Final	Original	1	1					1	
	Ľ		L	L	L	L	1		1.	1
		51			Γ	T		T	1	
		52				1	1	1		
		53	<u> </u>	1		T	1	1	1	1
		54	_	+	-	1	+-	+	1	
	-	55		1	1-	1	+	+-	1	
1.0	-	56	-	+-	├	+	+	+-	+	
	-	57	-	-	 	\vdash	+-	+	├	
	-		<u> </u>	₩	-	-	+	+	-	<u> </u>
	-	58	<u> </u>	-	-	 	1	1-		
		59		<u> </u>	<u> </u>	-	↓	-	ļ	
		60	Ŀ	<u> </u>	L	<u> </u>	<u> </u>			
, <u>,</u> <u>,</u> <u>,</u> <u>, </u>		61		<u> </u>		1.		1		
		62	1 5		L					
		63		L			L		<u> </u>	
*		64						1		
		65				1	T	1	1	
. ,		66		 		1	\vdash	1	t	
		67		 	_	+-	 	†		
		68		\vdash	 		+-	+	 	<u> </u>
:	_				-	 	├			<u> </u>
	-	69	<u>i</u>	-		⊢	\vdash	 	<u> </u>	
		70					_	:		
		71								
		72			L	L				
	-	73								
. "		74							1	
		75					-	<u> </u>		
	-	76					<u> </u>	1		
		77	+	-		-	 	1		
· . }		78		-		-	 	1	-	<u> </u>
									-	
		79				_	-	<u> </u>		ــــــــــــــــــــــــــــــــــــــ
lejected	_	80	_		-	<u> </u>	_	<u> </u>	_	
Allowed anceled		81		<u> </u>		ļ.,.	<u> </u>	-	-	
Restricted		82		L	<u>. </u>	_	_		<u> </u>	
fon-elected nterference		83				<u> </u>	Ľ.			
opeal Diected		84								
bjected .		85								1. 1
		86								
1		87			•					
*		88			- ,					
	\dashv	89	_				<u> </u>			
·	\dashv	90				-	_	-		
· .		91			·		\vdash			
-	-+									
ļ		92						<u> </u>	-	
	\rightarrow	93	_		,					·
		94				-				
	-	95							-	
L		96								!
		97								
		98								
	- 1									
	-	99			\neg					-

1-B3

(LEFT INSIDE)

خترا	عينت حني	× ×		
		SEAF	RCHEE)
	Class	Sub.	Date	Exmr.
	424	049	12/19/16	cwng
The second secon	426	607 049 049 049 049 049 049 049 049 049 049	5/22/197	Llumj
・ 「	426	० मु म म म म म म म म म म म म म म म म म म	8/12/97	i Wing

ERENC	CE SEAR	CHED
Sub.	Date	Exmr.
049 052 615 425 429 431	8/13/97	L\Wmg
	Sub. 049 052 052 405 425	049 052 615 425

		. (.	5/2:)
0	عالماء	c*/>	2100	`
,			5/20	~
			my I char in	MIL. MA

SEARCH N	NOTES	
	Date	Exmr.
· M5	12/19/18	o cuany
		Ø.

1-B4 (RIGHT OUTSIDE)

JED W. FAHEY, ELDERSBURG, MD; PAUL TALALAY, BALTIMORE, MD. **CONTINUING DATA************** VERIFIED **FOREIGN/PCT APPLICATIONS******* VERIFIED **TATE OR SHETS DAWING CLAIMS CLAIMS CLAIMS RECEIVED CLAIMS DOUNTRY DAWING CLAIMS S2,084.00 46528/102/JO **STATE OR SHETS DOUNTRY DOUNTRY DOUNTRY DOUNTRY DOUNTRY DOUNTRY DAWING CLAIMS S2,084.00 46528/102/JO **GOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109		U.S. P	ATENT A	PPLICATION
JED W. FAHEY, ELDERSBURG, MD; PAUL TALALAY, BALTIMORE, MD. **CONTINUING DATA****************** VERIFIED **FOREIGN/PCT APPLICATIONS******** VERIFIED FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT FLING FEE ATTORNEY DOCKET NO. CLAIMS RECEIVED ATTORNEY DOCKET NO. 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SULTE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS				1 1 3 5
JED W. FAHEY, ELDERSBURG, MD; PAUL TALALAY, BALTIMORE, MD. **CONTINUING DATA*************** VERIFIED **FOREIGN/PCT APPLICATIONS******* VERIFIED FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL CLAIMS RECEIVED RECEIVED ATTORNEY DOCKET NO. CLAIMS RECEIVED S2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109	SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT
CONTINUING DATA******************* VERIFIED **FOREIGN/PCT APPLICATIONS******** VERIFIED FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT CLAIMS RECEIVED ATTORNEY DOCKET NO. CLAIMS MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	08/528,858	09/15/95	426	1302
CONTINUING DATA************** VERIFIED **FOREIGN/PCT APPLICATIONS******** VERIFIED FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT FILING FEE ATTORNEY DOCKET NO. CLAIMS CLAIMS RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	JED W. FAHEY, ELDERSBURG, M	D; PAUL TALALAY,	BALTIMORE, MD	
CONTINUING DATA************** VERIFIED **FOREIGN/PCT APPLICATIONS******** VERIFIED FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT FILING FEE ATTORNEY DOCKET NO. CLAIMS CLAIMS RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	PLIC 			
FOREIGN/PCT APPLICATIONS***** VERIFIED **FOREIGN FILING LICENSE GRANTED 12/19/95 TATE OR SHEETS TOTAL INDEPENDENT FILING FEE ATTORNEY DOCKET NO. CLAIMS CLAIMS RECEIVED ATTORNEY DOCKET NO. \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS		****		
FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT CLAIMS RECEIVED ATTORNEY DOCKET NO. CLAIMS CLAIMS \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	,			*
FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT CLAIMS FEE RECEIVED ATTORNEY DOCKET NO. MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS				
FOREIGN FILING LICENSE GRANTED 12/19/95 STATE OR SHEETS TOTAL INDEPENDENT CLAIMS RECEIVED ATTORNEY DOCKET NO. CLAIMS CLAIMS \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	i			
FOREIGN FILING LICENSE GRANTED 12/19/95 TATE OR SHEETS TOTAL INDEPENDENT CLAIMS RECEIVED ATTORNEY DOCKET NO. MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS		<u>.</u>		V •
FOREIGN FILING LICENSE GRANTED 12/19/95 TATE OR SHEETS TOTAL INDEPENDENT CLAIMS FEE RECEIVED ATTORNEY DOCKET NO. MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	;			
TATE OR SHEETS TOTAL CLAIMS INDEPENDENT FILING FEE RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	• •	*****	Α,	
TATE OR SHEETS TOTAL CLAIMS INDEPENDENT FILING FEE RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS			, 1	
TATE OR SHEETS TOTAL CLAIMS INDEPENDENT FILING FEE RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS			*	
TATE OR SHEETS TOTAL CLAIMS INDEPENDENT FILING FEE RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS				
TATE OR SHEETS TOTAL CLAIMS INDEPENDENT FILING FEE RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS			· \	
DRAWING CLAIMS CLAIMS RECEIVED MD 2 47 13 \$2,084.00 46528/102/JO FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS				
FOLEY AND LARDNER 3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS			FILING FEE RECEIVED	ATTORNEY DOCKET NO.
3000 K STREET NW SUITE 500 WASHINGTON DC 20007-5109 CANCER CHEMOPROTECTIVE FOOD PRODUCTS	MD 2 47	13	\$2,084.00	46528/102/JO
CANCER CHEMOPROTECTIVE FOOD PRODUCTS	FOLEY AND LARDNER		• ,	X
CANCER CHEMOPROTECTIVE FOOD PRODUCTS	SUITE 500			· · · · · · · · · · · · · · · · · · ·
CANCER CHEMOPROTECTIVE FOOD PRODUCTS	WASHINGTON DC 20007-5109		•	
	CANCER CHEMOPROTECTIVE FOO	D PRODUCTS		
	<u></u>			
	The second secon			•

Law Offices FOLEY & LARDNER Suite 500 5000 K Street, N.W. Washington, DC 20007-5109 (202) 672-5300

missioner for Patents Washington, D. C. 20231

sir:

Transmitted herewith for filing is the patent application of:

INVENTOR (S): Jed W. FAHEY, Paul TALALAY

CANCER CHEMOPROTECTIVE FOOD PRODUCTS TITLE:

In connection with this application, the following are enclosed:

- 44 Pages of Specification with Abstract
- 47 Claims
- 2 Sheets of Drawings
- _XX_ Declaration, Power of Attorney
- XX Assignment to: Johns Hopkins School of Medicine
- __ Certified Priority Application and Priority Claim
- Statement of Small Entity Status

The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

(1) For	(2) Number Filed	(3) Number Extra	(4) Rate	(5) Basic Fee \$730 (\$365)
Total Claims	47 - 20 =	27	x \$22 (x \$11)	594.00
Indergndent Claims	14 - 3 =	11	x \$76 (x \$38)	836.00
Multiple Dependent Claims			\$240 (\$120)	_
Assignment Re	cording Fee	\$ 40	40.00	
			TOTAL FEE:	\$2,200.00

A check in the amount of the above TOTAL FEE is attached. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,

Date: September 15, 1995 Docket No.: 46528/102/JOHO

Bernhard D. Saxe Req. No. 28,665

September 15, 1995

1-B7

Return to: BDS:tl:RCP:wh Inspected by:

BUS. RCP. WH NEW RP, ASSIGN

REF - 40906 SEP 15 1995

PATENT APPLICATION SERIAL NO

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

110 MG 10/11/95 08528858

SE18051 12/11/95 08528858

1 101 2,160.00 CK 46528/102/JD #-76.00CR \$ 78.00 Bp

19-0741 180 101

1-B8

15

20

25

30 .

Inventors:

Jed W. Fahey

Paul Talalay

METHOD OF PREPARING A FOOD PRODUCT FROM CRUCIFEROUS SEEDS

CANCER CHEMOPROTECTIVE FOOD PRODUCTS

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant PO1 CA 44530, entitled "Novel Strategies for Chemoprotection Against Cancer", (Paul Talalay, Principal Investigator) awarded by the National Cancer Institute, Department of Health and Human Services.

BACKGROUND OF THE INVENTION

Field of Invention

This invention relates to a dietary approach to reducing the level of carcinogens in animals and their cells and thereby reducing the risk of developing cancer. In particular, this invention relates to the production and consumption of foods which are rich in cancer chemoprotective compounds. More specifically, this invention relates to chemoprotective compounds that modulate mammalian enzymes which are involved in This invention relates to metabolism of carcinogens. food sources which are extremely rich in compounds that induce the activity of Phase 2 enzymes, without inducing biologically significant activities of those Phase 1 enzymes that activate carcinogens.

II. Background

It is widely recognized that diet plays a large role in controlling the risk of developing cancers and that increased consumption of fruits and vegetables reduces cancer incidence in humans. It is believed that a major mechanism of protection depends on the presence of chemical components in plants that, when delivered to

10

15

20

25

30

35

mammalian cells, elevate levels of Phase 2 enzymes that detoxify carcinogens.

Early studies on the mechanism of chemoprotection by certain chemicals assumed that these chemoprotectors induced activities of monooxygenases, also known as Phase 1 enzymes or cytochromes P-450. However, Talalay et al., [reviewed in "Chemical Protection Against Cancer by Induction of Electrophile Detoxication (Phase In: CELLULAR AND MOLECULAR Enzymes" TARGETS CHEMOPREVENTION, L. Wattenberg et al., CRC Press, Boca FL, pр 469-478 (1992)] determined administration of the known chemoprotector butylated hydoxyanisole (BHA) to rodents resulted in little change in cytochromes P-450 (Phase 1 enzyme) activities, but profoundly elevated Phase 2 enzymes. Phase 2 enzymes such as glutathione stransferases, NAD(P)H:quinone reductase (QR) and glucuronosyltransferases, detoxify DNA-damaging electrophilic forms of ultimate carcinogens. Selective inducers of Phase 2 enzymes are designated monofunctional inducers. Prochaska & Talalay, Cancer Res. 48: 4776-4782 (1988). The monofunctional inducers are nearly all electrophiles and belong to 8 distinct classes including (1) diphenols, phenylenediamines and quinones; (2) Michael reaction acceptors containing olefins or acetylenes conjugated to electron-withdrawing groups; (3) isothiocyanates; (4) 1,2-dithiole-3-thiones; (5) hydroperoxides; (6) trivalent inorganic and organic arsenic derivatives; (7) heavy metals with potencies related to their affinities for thiol groups including Hg^{2+} , and Cd^{2+} ; and (8) vicinal dimercaptans. Prestera et al., Proc. Natl. Acad. Sci. USA 90: 2963-2969 (1993). The only apparent common property shared by all of these inducers is their ability to react with thiol groups.

Chemoprotective agents can be used to reduce the susceptibility of mammals to the toxic and neoplastic effects of carcinogens. These chemoprotectors can be of

plant origin or synthetic compounds. Synthetic analogs of naturally occurring inducers have also been generated and shown to block chemical carcinogenesis in animals. Posner et al., J. Med. Chem. 37: 170-176 (1994); Zhang et al., Proc. Natl. Acad. Sci. USA 91: 3147-3150 (1994); Zhang et al., Cancer Res. (Suppl) 54: 1976s-1981s (1994).

Highly efficient methods have been developed for measuring the potency of plant extracts to increase or induce the activities of Phase 2 enzymes. Prochaska & Santamaria, Anal. Biochem. 169: 328-336 (1988) and Prochaska et al., Proc. Natl. Acad. Sci. USA 89: 2394-2398 (1992). In addition, these methods have been employed for isolating the compounds responsible for the inducer activities in plants and for evaluating the anticarcinogenic activities of these compounds and their synthetic analogs. Zhang et al., Proc. Natl. Acad. Sci. USA 89: 2399-2403 (1992) and Posner et al., J. Med. Chem. 17: 170-176 (1994).

10

15

20

25

30

35

Although inducer activity has been found in many different families of edible plants, the amounts are highly variable, depending on family, genus, species, variety, or cultivar of the plant selection and on growth and harvesting conditions. Thus, there is a need in the art to identify particular edible plants and methods of growing and preparing them that yield high levels of Phase 2 enzyme-inducer activity for chemoprotection. There is also a need for methods of growing and preparing edible plants that produce a known spectrum of specific inducers of Phase 2 enzyme activity in order to increase the efficiency with which specific carcinogens, or classes of carcinogens, are targeted for inactivation. In addition, there is a need for methods of plant breeding and selection to increase the level of Phase 2 inducer activity and to manipulate the spectrum of inducers produced in particular cultivars.

15

20

25

30

4

SUMMARY OF THE INVENTION

It is an object of the present invention to provide food products and food additives that are rich in cancer chemoprotective compounds.

Another object of the present invention is to provide food products which contain substantial quantities of Phase 2 enzyme-inducers and are essentially free of Phase 1 enzyme-inducers.

It is a further object of the present invention to provide food products which contain substantial quantities of Phase 2 enzyme-inducing potential and non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates.

These objects, and others, are achieved by providing cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage. The cruciferous sprouts include Brassica oleracea varieties acephala, alboglabra, botrytis, costata, gemmifera, gongylodes, italica, medullosa, palmifolia, ramosa, sabauda, sabellica, and selensia.

Another embodiment of the present invention provides cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage, wherein the sprouts are substantially free of Phase 1 enzyme-inducing potential.

Yet another embodiment of the present invention provides a non-toxic solvent extract of cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage. The non-toxic solvent extract can be a water extract. In addition, the water extract can comprise a cruciferous vegetable, such as a cruciferous vegetable of the genus Raphanus, comprising an active myrosinase enzyme.

Page 13 of 25

Another embodiment of the present invention provides a food product comprising cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage; extracts of the sprouts or cruciferous seeds; or any combination of the sprouts or extracts.

A further embodiment of the present invention provides a method of increasing the chemoprotective amount of Phase 2 enzymes in a mammal, comprising the step of administering an effective quantity of cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage.

10

15

20

25

30

35

Yet another embodiment of the present invention provides a method of increasing the chemoprotective amount of Phase 2 enzymes in a mammal, comprising the step of administering an effective quantity of a food product comprising cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage.

Another embodiment of the present invention provides cruciferous sprouts harvested prior to the 2-leaf stage, wherein the sprouts have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce said sprouts and contain non-toxic levels of indole their breakdown products glucosinolates and The goitrogenic hydroxybutenyl glucosinolates. cruciferous sprouts include Brassica oleracea varieties acephala, alboglabra, botrytis, costata, gemmifera, gongylodes, italica, medullosa, palmifolia, ramosa, sabauda, sabellica, and selensia.

A further embodiment of the present invention provides a food product comprising sprouts harvested prior to the 2-leaf stage, wherein the sprouts have at

15

20

25

30

35

"least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days from growth of seeds that produce the sprouts and contain montoxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates; extracts of the sprouts or cruciferous seeds; or any combination of the sprouts or extracts.

Yet another embodiment of the present invention provides cruciferous sprouts harvested prior to the 2leaf stage, wherein the sprouts have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and contain non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates substantially free of Phase 1 enzyme-inducing potential.

Another embodiment of the present invention provides a non-toxic solvent extract of cruciferous sprouts harvested prior to the 2-leaf stage, wherein the sprouts have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and contain non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates. The non-toxic solvent extract can be a In addition, the water extract can water extract. comprise a cruciferous vegetable, such as a cruciferous vegetable of the genus Raphanus, comprising an active myrosinase enzyme.

Yet another embodiment of the present invention provides a method of increasing the chemoprotective amount of Phase 2 enzymes in a mammal, comprising the an effective step of administering cruciferous sprouts harvested prior to the 2-leaf stage, wherein the sprouts have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when

10

15

20

25

3Ò

35

measured after 3 days of growth from seeds that produce the sprouts and contain non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates.

Yet another embodiment of the present invention provides a method of increasing the chemoprotective amount of Phase 2 enzymes in a mammal, comprising the step of administering an effective quantity of a food product comprising sprouts harvested prior to the 2-leaf stage, wherein the sprouts have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and contain non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates.

A further embodiment of the present invention provides a method of preparing a food product rich in glucosinolates, comprising germinating cruciferous seeds, with the exception of cabbage, cress, mustard and radish seeds, and harvesting sprouts prior to the 2-leaf stage to form a food product comprising a plurality of sprouts. The cruciferous sprouts include Brassica oleracea varieties acephala, alboglabra, botrytis, costata, gemmifera, gongylodes, italica, medullosa, palmifolia, ramosa, sabauda, sabellica, and selensia and contain nontoxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates.

Yet another embodiment of the present invention provides a food product rich in glucosinolates made by germinating cruciferous seeds, with the exception of cabbage, cress, mustard and radish seeds, and harvesting sprouts prior to the 2-leaf stage to form a food product comprising a plurality of sprouts.

Yet another embodiment of the present invention provides a method of preparing a food product comprising

extracting glucosinolates and isothiocyanates from cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts, harvested prior to the 2-leaf stage, with a non-toxic solvent and recovering the extracted glucosinolates and isothiocyanates. Myrosinase enzyme, or a vegetable, such as Raphanus species, containing the enzyme is mixed with the cruciferous sprouts, the extract, or both the sprouts and the extract.

10

15

20

25

30

35

An embodiment of the present invention provides a preparing a food product glucosinolates, comprising germinating cruciferous seeds having at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and which contain non-toxic levels of indole glucosinolates breakdown products and hydroxybutenyl glucosinolates, and harvesting sprouts prior to the 2-leaf stage to form a food product comprising a plurality of sprouts, The seeds may be Brassica oleracea, including the varieties acephala, alboglabra, botrytis, costata, gemnifera, gongylodes, italica, medullosa, palmifolia, ramosa, sabauda, sabellica, and selensia.

Yet another embodiment of the present invention provides a food product rich in glucosinolates made by germinating cruciferous seeds having at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and which contain non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates, and either harvesting sprouts at the 2-leaf stage to form a food product comprising a plurality of sprouts. The nutritional product contains non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates.

15

20

25

30

35

further embodiment of the present invention provides a method of preparing a food product comprising extracting glucosinolates and isothiocyanates with a solvent from cruciferous seeds, sprouts, plants or plant parts, wherein seeds that produce the sprouts, plants or plant parts producing sprouts having at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth and wherein the seeds, sprouts, plants or plant parts have non-toxic levels of indole glucosinolates and their breakdown products and goitrogenic hydroxybutenyl glucosinolates, and recovering the extracted glucosinolates and isothiocyanates. The non-toxic extraction solvent can be water. Myrosinase enzyme, or a vegetable, such as Raphanus species, containing the enzyme is mixed with the cruciferous sprouts, seeds, plants, plant parts or extract, or any combination thereof.

A further embodiment of the present invention provides a method of reducing the level of carcinogens in mammals, comprising administering cruciferous sprouts, with the exception of cabbage, cress, mustard and radish sprouts.

Yet another embodiment of the present invention provides a method of reducing the level of carcinogens in mammals, comprising administering cruciferous sprouts having at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when measured after 3 days of growth from seeds that produce the sprouts and non-toxic levels of indole glucosinolates and their hydroxybutenyl goitrogenic breakdown products and glucosinolates.

Another embodiment of the present invention provides a method of preparing a food product by introducing cruciferous seeds, having at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential when

15

20

25

30

measured after 3 days of growth from seeds that produce the sprouts and non-toxic levels of indole glucosinolates and goitrogenic hydroxybutenyl glucosinolates, into an edible ingredient.

A further embodiment of the present invention provides a method of extracting glucosinolates and isothiocyanates from plant tissue which comprises homogenizing the plant tissue in an excess of a mixture dimethyl sulfoxide, acetonitrile, dimethylformamide (DMF/ACN/DMSO) at a temperature that prevents myrosinase activity.

Another embodiment of the present invention provides cruciferous sprouts harvested prior to the 2-leaf stage, wherein the ratio of monofunctional to bifunctional inducers is at least 20 to 1.

Another object of the present invention is to provide a food product supplemented with a purified or partially purified glucosinolate.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the total inducing potential of organic solvent extracts of broccoli and daikon cultivars as a function of age.

Figure 2 shows the high resolution NMR spectra of isolated glucosinolates obtained from hot aqueous extracts of 3-day old Saga broccoli sprouts.

DETAILED DESCRIPTION

I. Definitions

20

25

30

In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the invention.

A bifunctional inducer is a molecule which increases activities of both Phase 1 enzymes such as cytochromes P-450 and Phase 2 enzymes and requires the participation of Aryl hydrocarbon (Ah) receptor and its cognate Xenobiotic Response Element (XRE). Examples include flat planar aromatics such as polycyclic hydrocarbons, azo dyes or 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD).

A chemoprotector or chemoprotectant is a synthetic or naturally occurring chemical agent that reduces susceptibility in a mammal to the toxic and neoplastic effects of carcinogens.

A food product is any ingestible preparation containing the sprouts of the instant invention, or extracts or preparations made from these sprouts, which are capable of delivering Phase 2 inducers to the mammal ingesting the food product. The food product can be freshly prepared such as salads, drinks or sandwiches containing sprouts of the instant invention. Alternatively, the food product containing sprouts of the instant invention can be dried, cooked, boiled, lyophilized or baked. Breads, teas, soups, cereals, pills and tablets, are among the vast number of different food products contemplated.

Inducer activity or Phase 2 enzyme-inducing activity
is a measure of the ability of a compound(s) to induce

15

20

25

3.0

35

Phase 2 enzyme activity. In the present invention, inducer activity is measured by means of the murine hepatoma cell bioassay of QR activity in vitro. Inducer activity is defined herein as QR inducing activity in Hepa 1c1c7 cells (murine hepatoma cells) incubated with extracts of sprouts, seeds or other plant parts untreated with myrosinase. Inducer activity is measured in Hepa 1c1c7 murine hepatoma cells grown in 96-well microtiter plates. Typically 10,000 Hepa 1c1c7 cells are introduced into each well. Hepatoma cells are grown for 24 hours and a plant extract containing microgram quantities of fresh plant tissue is serially diluted across the microtiter plates into fresh culture medium containing 0.15 ml αMEM culture medium amended with 10% Fetal Calf Serum (FCS) and streptomycin and penicillin. are further incubated for 48 hours. QR activity (based on the formation of the blue-brown reduced tetrazolium dye) is measured with an optical microtiter plate scanner in cell lysates prepared in one plate, and related to its protein concentration. Quantitative information on specific activity of QR is obtained by computer analysis of the absorbances. One unit of inducer activity is the amount that when added to a single microtiter well doubles the QR activity. (See Prochaska and Santamaria, Anal. Biochem. 169: 328-336 (1988) and Prochaska et al., Proc. Natl. Acad. Sci. USA 89: 2394-2398 (1992)).

Inducer potential or Phase 2 enzyme-inducing potential is a measure of the combined amounts of inducer activity in plant tissue provided by isothiocyanates, plus glucosinolates that can be converted by myrosinase to isothiocyanates. Glucosinolates are not themselves inducers of mammalian Phase 2 enzymes, isothiocyanates are inducers. Inducer potential therefore is defined herein as QR activity in murine 1c1c7 hepatoma cells incubated with myrosinase-treated extracts of the sprouts, seeds or other plant parts. In the present invention therefore inducer potential is measured by means of the murine hepatoma cell bioassay of

15

20

25

3.0

35

Filed 05/08/2008

QR activity in vitro as described above. potential is measured in Hepa 1c1c7 murine hepatoma cells grown in 96-well microtiter plates. Typically, 10,000 Hepa 1c1c7 cells are introduced into each well. Hepatoma cells are grown for 24 hours and a plant extract containing microgram quantities of fresh plant tissue is serially diluted across the microtiter plates into fresh culture medium containing 0.15 ml αMEM culture medium amended with 10% Fetal Calf Serum (FCS) and streptomycin and penicillin. Myrosinase (6 units/ml plant extract) is added to the plant extract. Myrosinase is purified by modification of the technique of Palmieri et al., Anal. Biochem. 35: 320-324 (1982) from 7 day old Daikon sprouts grown on agar support containing no added nutrients. Following 234-fold purification, the myrosinase had a specific activity of 64 units/mg protein [unit = amount of enzyme required to hydrolyze 1 μ mol sinigrin/min]. Plant extract is diluted 200-fold into the initial wells of the microtiter plate followed by 7 serial dilutions. The cells are further incubated for 48 hours. activity (based on the formation of the blue-brown reduced tetrazolium dye) is measured with an optical microtiter plate scanner in cell lysates prepared in one and related to its protein concentration. Quantitative information on specific activity of QR is obtained by computer analysis of absorbances. One unit of inducer potential is the amount that when added to a single microtiter well doubles the QR activity. Prochaska and Santamaria, Anal. Biochem. 169: 328-336 (1988) and Prochaska et al., Proc. Natl. Acad. Sci. USA 89: 2394-2398 (1992)).

A monofunctional inducer increases the activity of Phase 2 enzymes selectively without significantly altering Phase 1 enzyme activities. Monofunctional inducers do not depend on a functional Ah receptor but enhance transcription of Phase 2 enzymes by means of an Antioxidant Responsive Element (ARE).

15

20

25

30

35

Filed 05/08/2008

A cruciferous sprout is a plant or seedling that is at an early stage of development following germination. Cruciferous seeds are placed in an environment in which they germinate and grow. cruciferous sprouts of the instant invention are harvested following seed germination through and including the 2-leaf stage. The cruciferous sprouts of instant invention have at least 200,000 units per gram fresh weight of Phase 2 enzyme-inducing potential at 3days following incubation under conditions in which cruciferous seeds germinate and grow.

II. Description

A major mechanism of protection provided by fruits and vegetables in reducing the cancer incidence in humans depends on minor chemical components which, when delivered to mammalian cells, elevate levels of Phase 2 enzymes that detoxify carcinogens. It has now been discovered that the anticarcinogenic activity of certain edible plants can be increased. Plants such as Brassica oleracea variety italica (broccoli) are normally not harvested until they form heads. By growing these plants only to the seedling or sprout stage, that is between the onset of germination and the 2-leaf stage, the levels of inducers of enzymes that detoxify carcinogens and protect against cancer can be increased at least five-fold over those found in commercial stage vegetables of the same cultivars. Often increases of between 10 and 1000-fold have been observed.

Harvesting plants at an early seedling or sprout stage, or otherwise arresting their growth, leads to the greatest inducer potential and yields a food product of a type to which consumers are already accustomed. The Phase 2 enzyme-inducing potential of such sprouts may be as much as several hundred times higher than that observed in adult, market stage vegetables obtained from the same seeds. Thus it is possible that humans can consume the same quantities of inducer potential by

15

20

25

30

35

eating relatively small quantities of sprouts, rather than large quantities of market-stage vegetables.

It has now been found that most of the inducer potential of crucifer plants is due to their content of isothiocyanates and their biogenic precursors, glucosinolates. Glucosinolates are converted to isothiocyanates by the enzyme myrosinase which is a thioglucosidase. Normally myrosinase and glucosinolates are separated in the cell and if the cell is damaged, with loss of compartmentalization, myrosinase comes into contact with glucosinolates, which are then converted to isothiocyanates.

In order to screen large numbers of edible plants and to evaluate the effects of environmental perturbation on Phase 2 enzyme-inducer potential in those vegetables, it was necessary to improve upon the previously described techniques for homogenization and extraction of those Techniques initially described for the vegetables. extraction of Phase 2 inducers from vegetables involved homogenization of the vegetables in cold water, lyophilization, extraction of the resultant powder with acetonitrile, filtration and evaporative concentration, Prochaska et al., Proc. Natl. Acad. Sci. USA 89: 2394-2398 (1992).

Following identification of sulforaphane as the principal Phase 2 inducer from broccoli, comparative extractions were performed into hot 80% methanol, yielding similar inducer activity as the aforementioned acetonitrile extracts. When myrosinase was added to these hot methanol extracts in which glucosinolates are freely soluble, there was a dramatic enhancement of the Phase 2 inducer activity of these extracts (data The deliberate conversion of summarized in Table 1). these glucosinolates to isothiocyanates using exogenous myrosinase thus gave a better index of the inducers for Phase 2 enzymes of the vegetables tested. It was thus

10

15

20

25

30

35

clear that the majority of the potential Phase 2 inducers in crucifers was usually present in whole plants as the glucosinolate precursors of isothiocyanates.

The preponderance of glucosinolates and the rapidity with which, upon wounding of cruciferous plant tissue, glucosinolates are converted to isothiocyanates, led to the development of an improved extraction procedure. By manipulation of solvent mixtures and of the water activity of fresh vegetable/solvent homogenates, a procedure was developed that permits both glucosinolate and isothiocyanate quantification from the same, non-concentrated sample. In addition to being the rate-limiting step in an extraction protocol, evaporative concentration allows volatile inducers to detection. The improved procedure is both simple and efficient, requiring only that the plant sample be completely homogenized in solvent. Using this technique, the present inventors have thus been able to demonstrate dramatic increases in the recovery of inducer activity and inducer potential from cruciferous vegetables over previously described techniques.

If fresh-picked vegetables are promptly and gently harvested, directly into organic solvents comprising a mixture of DMF/ACN/DMSO and a temperature that prevents myrosinase activity, both glucosinolates isothiocyanates are efficiently extracted into the organic solvent mixture. Preferably, the DMF, ACN and DMSO are mixed in equal volumes. However, the volumes of the three solvents in the mixture can be varied to optimize extraction of specific glucosinolates and isothiocyanates from any plant tissue. The temperature of the extraction mixture is preferably less than 0°C, and most preferably less than -50°C. The temperature of the extraction solvent must be kept above freezing. At the same time the enzyme myrosinase, which invariably accompanies these constituents in the plants and rapidly glucosinolates into isothiocyanates, converts

10

15

20

25

30

inactive. Such extracts typically contain high quantities of glucosinolates and negligible quantities of isothiocyanates. The *in planta* myrosinase activity varies between different plant species.

Glucosinolates are not themselves inducers of mammalian Phase 2 enzymes, whereas isothiocyanates are monofunctional inducers in the murine hepatoma cell bioassay of QR activity. The inducer potential, as distinct from inducer activity, of plant extracts can be measured by adding purified myrosinase, obtained from the same, or other plant sources, to the assay system.

Glucosinolates are converted at least partially to isothiocyanates in humans. If, however, it is desirable to accelerate this conversion, broccoli or other vegetable sprouts, high in glucosinolates, can be mixed with myrosinase. The mixture can be in water, or some other non-toxic solvent that does not inactivate myrosinase. The myrosinase can be from a partially purified or purified preparation. Alternatively, the myrosinase can be present in plant tissue, such as a small quantity of crucifer sprouts rich in myrosinase, including Raphanus sativus or daikon. Such a preparation can be used to produce a "soup" for ingestion that is high in isothiocyanates and low in glucosinolates. Inducer potential can be measured using a multiwell plate screen with murine hepatoma cells for in vitro measurement of QR specific activity as described above.

The ratio of monofunctional to bifunctional inducer activity of plant tissue is measured by bioassaying plant extracts, as described above, not only in wild-type Hepa 1c1c7 cells, but also, in mutants designated c1 and BP'c1 that have either defective Ah receptors or defective cytochrome P_1 -450 genes, respectively. Prochaska and Talalay, Cancer Research 48: 4776-4782 (1988).